Valeria Colicchia

Valeria Colicchia

Auto-generated profile, based on publicly available information

Valeria Colicchia

Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics Karolinska Institute Stockholm Sweden

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2017 in Oncogene
Verified
Journal Article
Closed access
VCV Colicchia
V Colicchia
MPMarialaura Petroni
Marialaura Petroni
GGGiulia Guarguaglini
Giulia Guarguaglini
FSF Sardina
F Sardina
MSM Sahún-Roncero
M Sahún-Roncero
GGGiueppe Giannini
Giueppe Giannini

22 April 2019 in PeerJ
Verified
Journal Article
Open access
PDF file
ANArianna Nicolussi
Arianna Nicolussi
FBFrancesca Belardinilli
Francesca Belardinilli
YMYasaman Mahdavian
Yasaman Mahdavian
VCValeria Colicchia
Valeria Colicchia
SDSonia D’iNzeo
Sonia D’iNzeo
ACAnna Coppa
Anna Coppa
Background: Conventional methods used to identify BRCA1 and BRCA2 germline mutations in hereditary cancers, such as Sanger sequencing/multiplex ligation-dependent probe amplification (MLPA), are time-consuming and expensive, due to the large size of the genes. The recent introduction of next-generation sequencing (NGS) benchtop platforms offered a powerful alternative for mutation detection, dramatically improving the speed and the efficiency of DNA testing. Here we tested the performance of the Ion Torrent PGM platform with the Ion AmpliSeq BRCA1 and BRCA2 Panel in our clinical routine of breast/ovarian hereditary cancer syndrome assessment. Methods: We first tested the NGS approach in a cohort of 11 patients (training set) who had previously undergone genetic diagnosis in our laboratory by conventional methods. Then, we applied the optimized pipeline to the consecutive cohort of 136 uncharacterized probands (validation set). Results: By minimal adjustments in the analytical pipeline of Torrent Suite Software we obtained a 100% concordance with Sanger results regarding the identification of single nucleotide alterations, insertions, and deletions with the exception of three large genomic rearrangements (LGRs) contained in the training set. The optimized pipeline applied to the validation set (VS), identified pathogenic and polymorphic variants, including a novel BRCA2 pathogenic variant at exon 3, 100% of which were confirmed by Sanger in their correct zygosity status. To identify LGRs, all negative samples of the VS were subjected to MLPA analysis. Discussion: Our experience strongly supports that the Ion Torrent PGM technology in BRCA1 and BRCA2 germline variant identification, combined with MLPA analysis, is highly sensitive, easy to use, faster, and cheaper than traditional (Sanger sequencing/MLPA) approaches.

11 September 2022 in FEBS Open Bio
Verified
Journal Article
Open access
VCValeria Colicchia
Valeria Colicchia
MHMaria Häggblad
Maria Häggblad
OSOleksandra Sirozh
Oleksandra Sirozh
BPBartlomiej Porebski
Bartlomiej Porebski
MBMirela Balan
Mirela Balan
OFOscar Fernandez-Capetillo
Oscar Fernandez-Capetillo
The tetracycline repressor (tetR)‐regulated system is a widely used tool to specifically control gene expression in mammalian cells. Based on this system, we generated a human osteosarcoma cell line, which allows for the inducible expression of an EGFP fusion of the TAR DNA‐binding protein 43 (TDP‐43), which has been linked to neurodegenerative diseases. Consistent with previous findings, TDP‐43 overexpression led to the accumulation of aggregates and limited the viability of U2OS. Using this inducible system, we conducted a chemical screen with a library that included FDA‐approved drugs. While the primary screen identified several compounds that prevented TDP‐43 toxicity, further experiments revealed that these chemicals abrogated the doxycycline‐dependent TDP‐43 expression. This antagonistic effect was observed with both doxycycline and tetracycline, and in several Tet‐On cell lines expressing different genes, confirming the general effect of these compounds as inhibitors of the tetR system. Using the same cell line, a genome‐wide CRISPR/Cas9 screen identified epigenetic regulators such as the G9a methyltransferase and TRIM28 as potential modifiers of TDP‐43 toxicity. Yet again, further experiments revealed that G9a inhibition or TRIM28 loss prevented doxycycline‐dependent expression of TDP‐43. In summary, we have identified new chemical and genetic regulators of the tetR system, thereby raising awareness of the limitations of this approach to conduct chemical or genetic screening in mammalian cells.